Alnylam predicts it will end 2014 with $825M to pay for drug trials

Alnylam Pharmaceuticals, fresh off a spotlight-stealing deal with Genzyme which effectively leaves it with more than $1 billion in cash, predicts it will end this year with $825 million in the bank, and will end 2015 with as many as seven drugs in human trials...